Literature DB >> 2341854

Chronic polyradiculoneuropathy associated with human T-cell lymphotropic virus type I infection.

K Arakawa, H Umezaki, S Noda, H Itoh.   

Abstract

Entities:  

Mesh：

Year:  1990        PMID： 2341854      PMCID： PMC1014182          DOI： 10.1136/jnnp.53.4.358-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

2.  Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection.

Authors:  D R Cornblath; J C McArthur; P G Kennedy; A S Witte; J W Griffin
Journal:  Ann Neurol       Date:  1987-01       Impact factor: 10.422

3.  Demyelinating neuropathy associated with hepatitis B virus infection. Detection of immune complexes composed of hepatitis B virus surface antigen.

Authors:  N Tsukada; C S Koh; A Inoue; N Yanagisawa
Journal:  J Neurol Sci       Date:  1987-02       Impact factor: 3.181

4.  Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment.

Authors:  M C Dalakas; W K Engel
Journal:  Ann Neurol       Date:  1981       Impact factor: 10.422
  4 in total
  2 in total

1.  Clinicopathological and virological analyses of familial human T-lymphotropic virus type I--associated polyneuropathy.

Authors:  Hirofumi Sawa; Toshiko Nagashima; Kazuo Nagashima; Toshiya Shinohara; Takayo Chuma; Yukio Mano; Nobutada Tachi; William W Hall
Journal:  J Neurovirol       Date:  2005-04       Impact factor: 2.643

2.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.